Characteristics of the patients at baseline
| Pirfenidone N=96 | |
| Age – years (range) | 67.1+/-8.1 (47–83) |
| Male sex - no (%) | 71 (73) |
| BMI (range) | 28+/-7.9 (14.4–43.4) |
| Former Smokers - no (%) | 64 (66%) |
| Duration of Treatment – months (range) | 9.3+/-8.3 (0–32) |
| FVC% Predicted (range) | 72.9+/-23.1 (46–146) |
| FVC 51–80% Predicted - no (%) | 69(72%) |
| FVC >80% Predicted – no (%) | 20 (20%) |
| DLCO% Predicted (range) | 43.6+/-19.9 (14–87) |
| DLCO <25% Predicted or unable – no (%) | 12 (12) |
| DLCO 26–35% Predicted – no (%) | 24 (25) |
| DLCO 36–65% Predicted – no (%) | 45 (47) |
| DLCO >66% Predicted – no (%) | 7 (7) |
| Use of supplementary oxygen - no (%) | 22 (23) |
| Use of prednisolone – no (%) | 26 (27) |
| Use of N-acetylcysteine – no (%) | 22 (22) |
Plus-minus values are means +/-SD.